Treatment of chronic myelomonocytic leukemia with azacitidine

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 878-880

  Wong, Eric ^a   Seymour, John F ^a,c   Kenealy, Melita ^b   Westerman, David ^a,c   Herbert, Kirsten ^a,b   Dickinson, Michael ^a,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b CABRINI INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; LACTATE DEHYDROGENASE; LENALIDOMIDE; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME 7; CHROMOSOME DELETION; CHRONIC MYELOMONOCYTIC LEUKEMIA; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; HOSPITALIZATION; HUMAN; LETTER; LEUKOCYTE COUNT; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; REMISSION; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL TIME;

AZACITIDINE; FEMALE; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE;

EID: 84879512426     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.730615     Document Type: Letter

References (15)

1. Fianchi L, Criscuolo M, Breccia M, et al. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: Results of an Italian retrospective study. Leuk Lymphoma 2012 Aug 30. [Epub ahead of print]
2. Kantarjian H, Issa J-PJ, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 2006; 106: 1794-1803.
3. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429-2440.
4. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
5. Swerdlow SH, Campo E, Harris NL, et al. WHO classifi cation of tumours of haematopoietic and lymphoid tumours. Lyon: International Agency for Research on Cancer; 2008: 1: 76-79.
6. Kenealy M, Giri P, Filshie R, et al. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes. Leuk Res 2011; 35(Suppl. 1): S22.
7. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modifi cation of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419-425.
8. Such E, Cervera J, Costa D, et al. Cytogenetic risk stratifi cation in chronic myelomonocytic leukemia. Haematologica 2011; 96: 375-383.
9. Beran M, Estey E, O' Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 1999; 17: 2819-2830.
10. Wattel E, Guerci A, Hecquet B, et al. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Fran ç ais des Myé lodysplasies and European CMML Group. Blood 1996; 88: 2480-2487.
11. Parikh SA, Teff eri A. C hronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratifi cation, and management. Am J Hematol 2012; 87: 610-619.
12. Osca-Gelis G, Puig-Vives M, Saez M, et al. Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): A populationbased study, 1993-2007. Leuk Res 2012; 36: 1262-1266.
13. Costa R, Abdulhaq H, Haq B, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011; 117: 2690-2696.
14. Th orpe M, Montalvã o A, Pierdomenico F, Moita F, et al. Treatment of chronic myelomonocytic leukemia with 5-azacitidine: A case series and literature review. Leuk Res 2012; 36: 1071-1073.
15. Choi S H, Byun H -M, Kwan J M, et al. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol 2007; 138: 616-623.